ArriVent BioPharma Stock Drops Over 50% After Late-Stage Cancer Trial Fails
ArriVent BioPharma (AVBP) experienced a significant stock decline of over 50% following the announcement that its late-stage clinical trial for firmonertinib failed to meet primary endpoints. The drug, an oral therapy targeting non-small cell lung cancer with EGFR mutations, was expected to be a key growth driver for the company. The failure marks a major setback in ArriVent's development pipeline and raises concerns about its future prospects without this lead candidate. Investors reacted strongly as biotech stocks are often highly sensitive to clinical trial outcomes, particularly when they represent a significant portion of a firm’s portfolio.
Tickers: $AVBP